April 11th 2024
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
July 18 - 20, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Tips for Sexual Well-Being After Treatment for Ovarian Cancer
April 1st 1999HOUSTON-The severity of sexual and fertility problems experienced by women after treatment for ovarian cancer is as diverse as the patient population, Leslie Schover, PhD, said at the First Annual International Conference for Ovarian Cancer, co-sponsored by M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center.
Revlon Second Annual Run/Walk for Women
April 1st 1999NEW YORK-Last year, more than 20,000 people took part in the 5-kilometer Revlon Run/Walk for Women in New York City, raising more than $700,000 to fight women’s cancers. This year’s event will take place on Saturday, May 1, following a route that runs from Times Square to Central Park. The event is produced by Rehage Entertainment, Inc. and the New York Road Runners Club in cooperation with the City of New York.
Activists and Scientists Join to Control Pollution Linked to Cancer
March 1st 1999ANAHEIM, California-Bringing together scientists and activists involved in understanding and controlling environmental pollutants associated with cancer can create powerful new research synergies, Sandra Steingraber, PhD, said at a symposium on mixed environmental hazards and cancer at the Annual Meeting of the American Association for the Advancement of Science (AAAS).
Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer, Part 3
There are several million breast cancer survivors worldwide. In the United States, 180,000 women were diagnosed with breast cancer in 1997, and approximately 97,000 of these women have an extremely low chance of a suffering a recurrence of their cancer. With an average age at diagnosis of 60 years and a 25-year expected duration of survival, the current number of breast cancer survivors in the United States may approach 2.5 million women. Since breast cancer is now being detected at an earlier stage than previously and since adjuvant chemotherapy may cause ovarian failure, an increasing number of women are becoming postmenopausal at a younger age after breast cancer treatment. This conference was convened in September 1997 to consider how menopausal breast cancer survivors should be treated at the present time and what future studies are needed to develop improved therapeutic strategies. A total of 47 breast cancer experts and 13 patient advocates participated. The proceedings of the conference are being published in six installments in successive issues of oncology. This third part focuses on the prevention of osteoporosis and the cardiovascular effects of estrogens and antiestrogens. [ONCOLOGY 13(3):397-432, 1999]
Oral Topotecan Appears Promising in Treatment of Ovarian Cancer and Small-Cell Lung Cancers
February 1st 1999NEW YORK-Although IV topo-tecan (Hycamtin) has been in use for several years and has shown activity in a number of different malignancies, oncologists now are turning their attention to delivering this camptothecin analog orally to maximize its effectiveness.
African-American Outreach Programs Require Planning, Sensitivity
February 1st 1999NEW YORK-Developing and implementing cancer outreach programs for African-Americans takes planning and sensitivity, said Robin L. Hurdle, CSW, a social worker in charge of the African-American Outreach Program at Cancer Care, Inc., the New York-based program that provides emotional support, information, and practical help to people with cancer and their loved ones free of charge.
Paraneoplastic Syndromes Earliest Sign of Some Cancers
February 1st 1999MONTREAL-Paraneoplastic syndromes are increasingly being recognized as the earliest warning signs of some cancers, according to presentations at the Presidential Symposium of the 123rd Annual Meeting of the American Neurological Association (ANA).
Late Recurrences May Be New Primaries in BRCA1 and BRCA2 Patients
January 1st 1999PHOENIX-A matched case-control study from Yale University suggests that early-stage breast cancer patients with deleterious BRCA1 or 2 mutations are at greater risk of late recurrences after breast-conserving surgery and radiation therapy than those without a mutation. Further, many of these late recurrences appear to be new primary breast cancers.
Hycamtin Is Approved for Use in Relapsed SCLC
January 1st 1999PHILADELPHIA-SmithKline Beecham’s topoisomerase I inhibitor Hycamtin (topotecan HCl for injection) has received FDA approval for the treatment of small-cell lung cancer (SCLC) after failure of first-line chemotherapy. The agent was previously approved for use in ovarian cancer after failure of initial or subsequent chemotherapy.
Cancer Chemoprevention: Hormones, Nonclassic Antioxidant Natural Agents, NSAIDs, and Other Agents
December 1st 1998This two-part series provides an up-to-date summary of the various chemopreventive agents currently in development and testing. Part 1, published in last month’s issue, focused on the retinoids, such as all-trans-
Progestin May Prevent Ovarian Cancers By Triggering Death of Damaged Ovarian Cells
November 1st 1998Researchers at Duke University Medical Center report animal studies that may explain, for the first time, why oral contraceptives offer protection against ovarian cancer. Their findings suggest that the progestin in birth control pills induces
Best Use of Breast Cancer Genetics Presents Clinical Challenge
November 1st 1998WASHINGTON--Genetic research has produced a growing body of information about the mutations related to breast cancer, but, so far, "no clear algorithm" to help clinicians decide how to use the new findings in the interests of patients, reported Francis S. Collins, MD, PhD, director of the National Human Genome Research Institute.
Progestin May Prevent Ovarian Cancers By Triggering Death of Damaged Ovarian Cells
November 1st 1998Researchers at Duke University Medical Center report animal studies that may explain, for the first time, why oral contraceptives offer protection against ovarian cancer. Their findings suggest that the progestin in birth control pills induces damaged ovarian cells to die before they turn malignant.
Cancer Chemoprevention Part 1: Retinoids and Carotenoids and Other Classic Antioxidants
November 1st 1998Cancer chemoprevention is the use of specific natural or synthetic substances with the objective of reversing, suppressing, or preventing carcinogenic progression to invasive cancer. Currently, numerous chemopreventive agents are in various stages of development and testing. Part 1 of this two-part series provides an overview of issues unique to chemoprevention trials, including the use of surrogate biomarkers as end points. This is followed by a discussion of the retinoids, such as all-trans-retinoic acid (ATRA [Vesanoid]), 9-cis-retinoic acid (9cRA), and isotretinoin (Accutane), and the carotenoids (eg, beta-carotene and lycopene) and other "classic" antioxidants (eg, vitamins E and C and selenium). Research on these agents will be delineated by disease site when applicable. Part 2, which will appear in next month’s issue, will focus on hormonally mediated chemopreventive agents, such as tamoxifen (Nolvadex), finasteride (Proscar), oral contraceptives, and dehydroepiandrosterone (DHEA). Part 2 also will cover nonantioxidant natural agents, such as calcium, the polyphenols, the isothiocyanates, and genistein; nonsteroidal anti-inflammatory drugs (NSAIDS), such as celecoxib, sulindac sulfone, and aspirin; difluro-methylornithine (DFMO [Eflornithine]); oltipraz; and N-acetylcysteine. [ONCOLOGY(11):1643-1658, 1998]
Intensive Effort Required to Develop a Breast Cancer Risk Assessment Clinic
September 1st 1998ATLANTA--Cancer programs and hospitals wishing to expand their services to include genetic counseling and testing should be aware that the staff and resource needs are intense, Constance Roche, MSN, RN, CS, said at a conference sponsored by the National Consortium of Breast Centers. Ms. Roche and Kevin Hughes, MD, who were instrumental in establishing the Lahey Clinic Risk Assessment Program, Peabody, Massachusetts, offered advice on establishing and operating such a program.
Advice Offered for Daughters of Women With Breast Cancer
September 1st 1998NEW YORK--Caring for a mother with advanced breast cancer can be a lot to deal with for a daughter. She has the tricky task of reversing roles with her mother. She may have a family of her own to care for--and there is the fear that she is at risk for cancer herself.
Physicians Must Weigh Risks and Benefits of Genetic Testing
September 1st 1998SAN FRANCISCO--Whether to administer genetic testing to a patient is a complex issue, Patrice Watson, PhD, of Creighton University School of Medicine, Omaha, said at the American Cancer Society Second National Conference on Cancer Genetics.
Oral MMPI Shows Promise as An Inhibitor of Angiogenesis
September 1st 1998LOS ANGELES--While the flurry of media attention on antiangiogenesis drugs has focused on angiostatin and endostatin, other such agents are further along in development. One of them, BAY 12-9566, has stopped tumor growth in patients for up to 11 months in an ongoing trial, Louise Grochow, MD, said at an ASCO session on novel approaches in drug development.
Consumer Advocates Win a Voice in NCI Programs
August 1st 1998BETHESDA, Md--As part of his sweeping reorganization and innovative effort at the National Cancer Institute, director Richard D. Klausner, MD, last November named 15 advocates to the Director’s Consumer Liaison Group (DCLG). Its recommendations will go directly to the NCI director, as it becomes a high-powered chartered advisory committee. Dr. Klausner envisioned a threefold purpose for this group of advocates. First, it will provide a forum for advocates to raise and discuss issues of concern regarding the development of NCI programs and research priorities. Second, it will help NCI develop criteria for selecting consumer advocates to serve on a number of NCI program and policy committees, including peer review panels. Third, it will serve as a strong link between NCI and cancer advocacy groups. Oncology News International’s Washington Bureau Chief Patrick Young discussed the DCLG’s role within NCI with Eleanor Nealon, director of NCI’s Office of Liaison Activities, which coordinates the group.
ODAC Recommends Approval of Topotecan for Second- Line Treatment of Small-Cell Lung Cancer
August 1st 1998The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended the approval of topotecan hydrochloride for injection (Hycamtin) for the second-line treatment of sensitive small-cell lung cancer (SCLC).
Vaccine Against HER2 Shows Promising Early Results
August 1st 1998LOS ANGELES--Bioengineered antibodies against HER2 received major attention at the the 34th Annual Meeting of the American Society of Clinical Oncology, but other approaches to HER2-expressing tumors are waiting in the wings. One uses an antitumor peptide vaccine to induce specific T-cell immunity to HER2. Another uses anti-HER2 immunoliposomes to steer intracellular delivery of antitumor drugs.
Cancer Care Adds Ovarian Cancer Section to Website
August 1st 1998NEW YORK--Cancer Care, Inc. has launched a new online resource for ovarian cancer patients and their families and friends. A new section added to Cancer Care’s website (www.cancercare.org) offers a comprehensive overview of ovarian cancer and a resource guide.
Leukemia Patients Sought for Participation in Worldwide Trial
August 1st 1998Two phase III, multicenter clinical trials are seeking patients to participate in studies evaluating PSC 833, an investigational agent,in combating multidrug resistance in patients with acute myelogenous leukemia. The studies, sponsored by Novartis,
Irinotecan in Lymphoma, Leukemia, and Breast, Pancreatic, Ovarian, and Small-Cell Lung Cancers
August 1st 1998Irinotecan (CPT-11 [Camptosar]) has a broad range of antitumor activity. Extensive preclinical and early clinical work has demonstrated its activity against many tumor types--head and neck, esophagus, stomach, pancreas,